+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Type 2 Diabetes Drugs Market by Drug (Injectables, Oral), Application (Cardiovascular Safety, Glycemic Control, Hypoglycemia Avoidance), Distribution - Forecast 2024-2030- Product Image
Global Type 2 Diabetes Drugs Market by Drug (Injectables, Oral), Application (Cardiovascular Safety, Glycemic Control, Hypoglycemia Avoidance), Distribution - Forecast 2024-2030- Product Image
Sale

Global Type 2 Diabetes Drugs Market by Drug (Injectables, Oral), Application (Cardiovascular Safety, Glycemic Control, Hypoglycemia Avoidance), Distribution - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5666390
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Type 2 Diabetes Drugs Market size was estimated at USD 71.17 billion in 2023, USD 77.07 billion in 2024, and is expected to grow at a CAGR of 8.81% to reach USD 128.55 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Type 2 Diabetes Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Type 2 Diabetes Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Type 2 Diabetes Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca, Bayer Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Peptron, Pfizer Inc., and Sanofi Group.

Market Segmentation & Coverage

This research report categorizes the Type 2 Diabetes Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Injectables
      • Aspart
      • Exenatide
      • Glargine
      • Insulin
      • Leraglutide
      • Pramlintide
    • Oral
      • Alpha-Glucosidase Inhibitors
      • Biguanides
      • Dipeptidyl Peptidase-4 Inhibitors
      • Glucagon-Like Peptide
      • Receptor Agonists
      • Secretagogues
      • Sodium Glucose Cotransport 2 Inhibitors
      • Sulfonylureas
      • Thiazolidinediones
  • Application
    • Cardiovascular Safety
    • Glycemic Control
    • Hypoglycemia Avoidance
  • Distribution
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Type 2 Diabetes Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Type 2 Diabetes Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Type 2 Diabetes Drugs Market?
  4. What is the market share of the leading vendors in the Type 2 Diabetes Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Type 2 Diabetes Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Type 2 Diabetes Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Significance of diabetic prevalence globally
5.1.1.2. Rise in obesity population coupled with unhealthy diets and sedentary lifestyles
5.1.1.3. Government initiatives and programs to create health awareness
5.1.2. Restraints
5.1.2.1. Products recall affecting brand reputation
5.1.3. Opportunities
5.1.3.1. Advancements in diabetic medications by pharmaceutical manufacturers
5.1.3.2. Rising investment in R&D and healthcare infrastructure development
5.1.4. Challenges
5.1.4.1. Stringent regulatory environment and time-consuming approval process
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Type 2 Diabetes Drugs Market, by Drug
6.1. Introduction
6.2. Injectables
6.3.1. Aspart
6.3.2. Exenatide
6.3.3. Glargine
6.3.4. Insulin
6.3.5. Leraglutide
6.3.6. Pramlintide
6.3. Oral
6.4.1. Alpha-Glucosidase Inhibitors
6.4.2. Biguanides
6.4.3. Dipeptidyl Peptidase-4 Inhibitors
6.4.4. Glucagon-Like Peptide
6.4.5. Receptor Agonists
6.4.6. Secretagogues
6.4.7. Sodium Glucose Cotransport 2 Inhibitors
6.4.8. Sulfonylureas
6.4.9. Thiazolidinediones
7. Type 2 Diabetes Drugs Market, by Application
7.1. Introduction
7.2. Cardiovascular Safety
7.3. Glycemic Control
7.4. Hypoglycemia Avoidance
8. Type 2 Diabetes Drugs Market, by Distribution
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Type 2 Diabetes Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Type 2 Diabetes Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Type 2 Diabetes Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. Amgen Inc.
13.1.3. AstraZeneca
13.1.4. Bayer Inc
13.1.5. Boehringer Ingelheim International GmbH
13.1.6. Bristol-Myers Squibb Company
13.1.7. Chugai Pharmaceutical Co., Ltd.
13.1.8. DAIICHI SANKYO COMPANY, LIMITED
13.1.9. Eli Lilly and Company
13.1.10. GSK plc
13.1.11. Johnson & Johnson Services, Inc.
13.1.12. Merck & Co., Inc.
13.1.13. Novartis AG
13.1.14. Peptron
13.1.15. Pfizer Inc.
13.1.16. Sanofi Group
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. TYPE 2 DIABETES DRUGS MARKET RESEARCH PROCESS
FIGURE 2. TYPE 2 DIABETES DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. TYPE 2 DIABETES DRUGS MARKET DYNAMICS
FIGURE 7. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 8. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 12. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. TYPE 2 DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 6. TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 8. TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. TYPE 2 DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 16. TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DIPEPTIDYL PEPTIDASE-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. TYPE 2 DIABETES DRUGS MARKET SIZE, BY RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECRETAGOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. TYPE 2 DIABETES DRUGS MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORT 2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. TYPE 2 DIABETES DRUGS MARKET SIZE, BY CARDIOVASCULAR SAFETY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYCEMIC CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. TYPE 2 DIABETES DRUGS MARKET SIZE, BY HYPOGLYCEMIA AVOIDANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 30. TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 49. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 50. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 51. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 52. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 55. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 56. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 57. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 76. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 77. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 78. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 79. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 81. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 82. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 83. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 84. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 89. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 91. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 92. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 93. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 94. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 99. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 104. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 109. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 114. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 119. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 121. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 122. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 123. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 124. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 129. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 137. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 138. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 139. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 140. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 142. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 143. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 144. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 145. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 147. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 148. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 149. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 150. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 153. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 154. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 155. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 157. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 158. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 159. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 160. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 165. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 167. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 168. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 169. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 170. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 182. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 183. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 184. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 185. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 187. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 188. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 189. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 190. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 192. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 193. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 194. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 195. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 212. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 213. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 214. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 215. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 220. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 228. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 229. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 230. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 242. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 243. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 244. TYPE 2 DIABETES DRUGS MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca
  • Bayer Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Peptron
  • Pfizer Inc.
  • Sanofi Group

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 77.07 Billion
Forecasted Market Value ( USD ) by 2030 $ 128.55 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Global Diabetes Drugs Market by Drug Type (Injectable Drug, Oral Drug), Application (Type 1 Diabetes, Type 2 Diabetes) - Forecast 2024-2030 - Product Image

Global Diabetes Drugs Market by Drug Type (Injectable Drug, Oral Drug), Application (Type 1 Diabetes, Type 2 Diabetes) - Forecast 2024-2030

  • Report
  • 198 Pages
  • Global
From
Global Type 1 Diabetes Drug Market by Form (Insulin Therapy, Oral Medication), End User (Drugstore, Hospital) - Forecast 2024-2030 - Product Image

Global Type 1 Diabetes Drug Market by Form (Insulin Therapy, Oral Medication), End User (Drugstore, Hospital) - Forecast 2024-2030

  • Report
  • 194 Pages
  • Global
From
Diabetes Drugs Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - Product Image

Diabetes Drugs Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis

  • Report
  • 220 Pages
  • Global
From
Global Incretin Based Drugs Market (2023 Edition): Analysis By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors), Route of Administration, By Indication, By Region, By Country: Market Insights and Forecast (2019-2029) - Product Image

Global Incretin Based Drugs Market (2023 Edition): Analysis By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors), Route of Administration, By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)

  • Report
  • 230 Pages
  • Global
From
Global Diabetes Devices and Therapeutics Business Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q2 2023 Update - Product Image

Global Diabetes Devices and Therapeutics Business Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q2 2023 Update

  • Report
  • 1300 Pages
  • Global
From

About the Type 2 Diabetes Drug Market

The Type 2 Diabetes Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat Type 2 Diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin properly. Type 2 Diabetes Drugs are used to help control blood sugar levels, reduce the risk of complications, and improve overall health. These drugs can be taken orally, injected, or inhaled. Common Type 2 Diabetes Drugs include Metformin, Sulfonylureas, Thiazolidinediones, Meglitinides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors. Some companies in the Type 2 Diabetes Drug market include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, Boehringer Ingelheim, and Takeda. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.